Compare PBH & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | IRON |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2004 | 2020 |
| Metric | PBH | IRON |
|---|---|---|
| Price | $56.72 | $66.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $75.33 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 520.1K | 370.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.88 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $975,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | $283.52 |
| P/E Ratio | $20.42 | ★ N/A |
| Revenue Growth | ★ 36.77 | N/A |
| 52 Week Low | $51.24 | $38.80 |
| 52 Week High | $88.00 | $99.50 |
| Indicator | PBH | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 55.22 |
| Support Level | N/A | $57.79 |
| Resistance Level | $63.56 | $69.36 |
| Average True Range (ATR) | 2.30 | 2.73 |
| MACD | -0.12 | 0.97 |
| Stochastic Oscillator | 46.32 | 74.85 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.